Differences in long-term outcome after femoral, subclavian and aortic approach to transcatheter aortic valve implantation (TAVI)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00078124" target="_blank" >RIV/00216224:14110/14:00078124 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Differences in long-term outcome after femoral, subclavian and aortic approach to transcatheter aortic valve implantation (TAVI)

Popis výsledku v původním jazyce

Introduction: Transcatheter aortic valve implantation (TAVI) represents an effective treatment of high-risk patients with severe aortic stenosis. There is no evidence of the long-term outcome of alternative approaches to TAVI. Aim: To asses the clinicaloutcome after subclavian and aortic TAVI compared to standard femoral approach. Methods: Prospective single-centre study comprise 228 consecutive TAVI patients (average age 79 years, logistic EuroSCORE 17.2, 53.5% females) divided in 1)Femoral, 2)Aorticand 3)Subclavian groups. More peripheral artery disease was found in both Aortic and Subclavian groups. The self-expandable CoreValve (Medtronic Inc., Minneapolis, MN USA) stented prosthesis was exclusively implanted. Results: In 99.6% the valve was successfully deployed. At 30 days the mortality and bleeding occurred in 2.6% and 3.5%, respectively, irrespective of the approach.

Název v anglickém jazyce

Differences in long-term outcome after femoral, subclavian and aortic approach to transcatheter aortic valve implantation (TAVI)

Popis výsledku anglicky

Introduction: Transcatheter aortic valve implantation (TAVI) represents an effective treatment of high-risk patients with severe aortic stenosis. There is no evidence of the long-term outcome of alternative approaches to TAVI. Aim: To asses the clinicaloutcome after subclavian and aortic TAVI compared to standard femoral approach. Methods: Prospective single-centre study comprise 228 consecutive TAVI patients (average age 79 years, logistic EuroSCORE 17.2, 53.5% females) divided in 1)Femoral, 2)Aorticand 3)Subclavian groups. More peripheral artery disease was found in both Aortic and Subclavian groups. The self-expandable CoreValve (Medtronic Inc., Minneapolis, MN USA) stented prosthesis was exclusively implanted. Results: In 99.6% the valve was successfully deployed. At 30 days the mortality and bleeding occurred in 2.6% and 3.5%, respectively, irrespective of the approach.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Experimental & clinical card

ISSN

1205-6626

e-ISSN

—

Svazek periodika

20

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

14

Strana od-do

2658-2671

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—